Volume 57, Issue 2, Pages (October 2000)

Slides:

Advertisements

Similar presentations

Renal registry in Hong Kong—the first 20 years Chi Bon Leung, Wai Lun Cheung, Philip Kam Tao Li Kidney International Supplements Volume 5, Issue 1, Pages.

Advertisements

Reduced renal function in patients with simple renal cysts

Effects of structured care by a pharmacist-diabetes specialist team in patients with Type 2 diabetic nephropathy Wilson Y.S. Leung, BPharm, PhD, Wing-Yee.

Plasma sodium and hypertension

Viper venom for diabetic nephropathy

Hydroxyethyl starch and change in renal function in patients undergoing coronary artery bypass graft surgery Wolfgang C. Winkelmayer, Robert J. Glynn,

Volume 83, Issue 3, Pages (March 2013)

Volume 58, Issue 1, Pages (July 2000)

From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria Paul E. De Jong, Barry M. Brenner Kidney International

Volume 61, Issue 4, Pages (April 2002)

Membranous nephropathy: When and how to treat

Viper venom for diabetic nephropathy

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Robert W. Schrier, Raymond.

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function Susan E. Shoaf, Patricia Bricmont, Suresh.

Progression of renal failure and hypertensive nephrosclerosis

Peter Rossing, Philip Hougaard, Hans-Henrik Parving

‘Progressive diabetic nephropathy. How useful is microalbuminuria

Volume 81, Issue 7, Pages (April 2012)

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Volume 63, Issue 3, Pages (March 2003)

Volume 77, Issue 8, Pages (April 2010)

How to interpret the eGFR in patients with small body surface area

Volume 54, Issue 4, Pages (October 1998)

Comorbidity and confounding in end-stage renal disease

Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load

Proinflammatory effects of iron sucrose in chronic kidney disease

Volume 70, Issue 11, Pages (December 2006)

Renal risk scores: Progress and prospects

Volume 54, Issue 5, Pages (November 1998)

The epidemiology of chronic kidney disease

Long-term study of mycophenolate mofetil treatment in IgA nephropathy

Volume 72, Issue 12, Pages (December 2007)

Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog,

Volume 68, Issue 2, Pages (August 2005)

Volume 58, Issue 1, Pages (July 2000)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 67, Issue 4, Pages (April 2005)

Reduced renal function in patients with simple renal cysts

Counteracting progression of renal disease: A look into the future

Volume 78, Issue 5, Pages (September 2010)

Volume 60, Issue 1, Pages (July 2001)

Lamivudine in hepatitis B-associated membranous nephropathy

Yasunori Kitamoto, Katsuhiko Matsuo, Kimio Tomita Kidney International

Volume 66, Pages S18-S21 (November 2004)

Volume 73, Issue 5, Pages (March 2008)

Phosphate binders on iron basis: A new perspective?

Volume 80, Issue 10, Pages (November 2011)

Volume 61, Issue 3, Pages (March 2002)

Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension Julian Segura, Carlos Campo, Luis M. Ruilope Kidney.

Volume 77, Issue 1, Pages (January 2010)

Volume 80, Issue 10, Pages (November 2011)

Volume 68, Pages S98-S102 (December 2005)

Volume 64, Issue 4, Pages (October 2003)

The hypothesis that abnormal BH4 metabolism impairs kidney function

Molecular and structural consequences of early renal allograft injury

H.J. Chin, H. Ro, H.J. Lee, K.Y. Na, D.-W. Chae Kidney International

Volume 62, Issue 5, (November 2002)

Volume 64, Issue 4, Pages (October 2003)

Volume 58, Issue 2, Pages (August 2000)

Volume 70, Issue 10, Pages (November 2006)

Volume 67, Issue 5, Pages (May 2005)

Volume 53, Issue 5, Pages (May 1998)

Friends, social networks, and progressive chronic kidney disease

Volume 69, Issue 11, Pages (June 2006)

Volume 61, Issue 4, Pages (April 2002)

Volume 57, Pages S44-S48 (April 2000)

Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases Martina Franz, Wolfgang Woloszczuk,

Effects of structured care by a pharmacist-diabetes specialist team in patients with Type 2 diabetic nephropathy Wilson Y.S. Leung, BPharm, PhD, Wing-Yee.

Volume 64, Issue 6, Pages (December 2003)

Presentation transcript:

Volume 57, Issue 2, Pages 590-600 (October 2000) Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients Juliana C.N. Chan, Gary T.C. Ko, Denis H.Y. Leung, Robert C.K. Cheung, Margaret Y.F. Cheung, Wing-Yee So, Ramasmyiyer Swaminathan, M. Gary Nicholls, Julian A.J.H. Critchley, Clive S. Cockram Kidney International Volume 57, Issue 2, Pages 590-600 (October 2000) DOI: 10.1046/j.1523-1755.2000.00879.x Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 1 Rates of deterioration of renal function, expressed as 24-hour creatinine clearance, in hypertensive type 2 diabetic patients, subdivided into normoalbuminuric (•), microalbuminuric (▪), and macroalbuminuric (▴) groups based on two of three 24-hour urinary albumin excretion measurements at baseline. Kidney International 2000 57, 590-600DOI: (10.1046/j.1523-1755.2000.00879.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 2 Effects of enalapril (□) and nifedipinetreatment on progression of renal function, expressed as regression coefficient of yearly plasma creatinine reciprocal (β-1/Cr) in hypertensive type 2 diabetic patients subdivided into normoalbuminuric, microalbuminuric, and macroalbuminuric groups based on two of three 24-hour urinary albumin excretion measurements at baseline. Kidney International 2000 57, 590-600DOI: (10.1046/j.1523-1755.2000.00879.x) Copyright © 2000 International Society of Nephrology Terms and Conditions